RALEIGH, NC (October 28, 2013) – DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to therapy and manage side effects arising from cancer treatment, today announced the signing of an agreement with Alamo Pharma Services, a subsidiary of Mission Pharmacal, for a twenty (20) person national sales team in the U.S. oncology market.
SAN ANTONIO, TX (August 21, 2013) – Urocit®-K (extended release potassium citrate), the proven urological treatment that blazed a trail into space to help NASA astronauts combat kidney stones, has begun a new journey here on Earth.
With the Urocit-K flagship leading the way, Mission Pharmacal Company has launched a new sales force to better deliver its entire fleet of urology medicines into the hands of physicians nationwide.
San Antonio, TX (January 26, 2012) – Mission Pharmacal Company announces the recent formation of Alamo Pharma Services. This new business unit, a wholly owned subsidiary of Mission, will provide pharmaceutical sales teams with operational and human resources (HR) support. Alamo will be headquartered in Doylestown, Pennsylvania, expanding Mission’s Northeastern United States presence which also includes the company’s Commercial Group operations and BioComp Pharma, Mission’s lifecycle management and generics company.